Localized delivery of hyaluronic acid-doxorubicin from a surgical paste for post-operative glioblastoma treatment
(2026) Materials Today Bio — Vol. 38, p. 103142 (2026)
Files
Materials Today Bio 2026 - 38 - 103142.pdf
Open Access - Adobe PDF
- 10.8 MB
Details
- Authors
Garofalo, Mariangela 
Malfanti, Alessio
- Abstract
- Glioblastoma stem cells (GSCs) and residual tumor cells-which resist conventional therapies, drive disease recurrence, and contribute to the formation of an immunosuppressive tumor-immune microenvironment (TIME)-represent a crucial barrier to the effective treatment of post-operative glioblastoma, the most aggressive and lethal primary brain tumor in adults. The cavity left after tumor resection represents a valuable opportunity to deliver therapeutics locally via the placement of conformable scaffolds for the immediate chemotherapeutic targeting of GSCs and residual glioblastoma cells. We hypothesized that Surgiflo™, a moldable, FDA-approved gelatin-based hemostatic paste, could serve as a dual-purpose platform that minimizes postoperative bleeding and functions as a conformable, local, and sustained drug-delivery system. We incorporated a pH-sensitive designed hyaluronic acid-doxorubicin polymer-drug conjugate (HA-DOX) into the Surgiflo™ matrix, exploiting HA's selective affinity for CD44 (highly expressed by both GBM and GSCs) and promoting the depletion of GBM and GSCs via immunogenic cell death (ICD)-inducing properties of DOX. In vitro studies of HA-DOX-containing paste confirmed enhanced HA-DOX uptake in GSC-enriched models, improved ICD induction in GBM cells, favorable biocompatibility, and sustained drug release. In vivo evaluations revealed that intracavitary implan-tation of the HA-DOX-containing paste significantly prolonged the median survival of treated mice compared to the untreated group (37 days vs 25 days, respectively) and modulated the glioblastoma-associated TIME, resulting in a 44% reduction in GSC levels and a significant increase in CD8 + T cell levels (*p < 0.5), compared to resected mice. Embedding HA-DOX within Surgiflo™ offers a promising strategy for localized, sustained delivery of chemotherapeutics to the resected cavity, with the potential to improve therapeutic outcomes and minimize systemic toxicity in postoperative glioblastoma treatment.
- Affiliations
Citations
Rodella, G., Pesce, C., Rampado, R., Garofalo, M., Wang, M., Ucakar, B., Vanvarenberg, K., Ma, Z., Joudiou, N., Préat, V., Gallez, B., & Malfanti, A. (2026). Localized delivery of hyaluronic acid-doxorubicin from a surgical paste for post-operative glioblastoma treatment. Materials Today Bio, 38, 103142. https://doi.org/10.1016/j.mtbio.2026.103142 (Original work published 2026)